SEPSIS: L. Plantarum Trial

Safety, Tolerability and Effects on the Microbiome of Neonatal Administration of Lactiplantibacillus Plantarum ATCC 202195 With or Without Fructooligosaccharide for One or Seven Days: a Phase II Randomized Placebo-controlled Trial in Dhaka, Bangladesh

Sepsis is a life-threatening clinical syndrome and a leading cause of neonatal deaths worldwide. The burden of neonatal sepsis and severe infection (SI) is particularly high in areas of South Asia and other resource-limited settings. The goal of the Synbiotics for the Early Prevention of Severe Infections in Infants (SEPSIS) phase II L. plantarum trial is to generate knowledge on the safety, tolerability and effects on the microbiome of Lactiplantibacillus plantarum, with or without fructooligosaccharide, in infants (birth to 60 days of age) in Dhaka, Bangladesh. All data generated will support the design and implementation of a phase III trial to test the efficacy of the probiotic/synbiotic or other interventions for the prevention of SI, promotion of optimal growth and development, and effects on other health outcomes in early infancy.

Study Overview

• Status: Completed
• Conditions: Microbial Colonization; Infant ALL; Tolerance; Safety Issues
• Intervention / Treatment: Other: Placebo; Dietary supplement: Synbiotic; Dietary supplement: Probiotic

Detailed Description

As a leading cause of neonatal morbidity and mortality, sepsis poses a common and serious threat for neonates. In 2017, sepsis, meningitis, and pneumonia accounted for an estimated 540,000 newborn deaths worldwide, or approximately one-fifth of the world's annual neonatal deaths. Previous studies have suggested that South Asia has a relatively high incidence of possible serious bacterial infection (pSBI) in young infants, particularly in areas where neonatal and under-five mortality rates are highest.

Recent randomized controlled trials (RCTs), including the Panigrahi et al. community-based trial in India, have demonstrated beneficial effects of probiotics and/or prebiotics, compared to placebo, for preventing infections in preterm and/or LBW infants. This is particularly important in low- and middle-income countries in Africa and South Asia, where low-cost preventative interventions to reduce the burden of SI (e.g., probiotics or synbiotics) could have an important impact on the burden of morbidity and mortality in young infants. However, there are limited data regarding the safety, tolerability and efficacy of L. plantarum ATCC 202195 in the general population of infants (rather than selected groups of preterm or hospitalized newborns) in South Asia.

This phase II trial will generate new evidence about the safety, tolerability and colonization effects of L. plantarum ATCC 2020195 in young infants (birth to 60 days of age) in Dhaka, Bangladesh. The aims of this study are to:

1. Estimate the effect of neonatal oral administration of Lactiplantibacillus plantarum (L. plantarum) ATCC 202195 (10^9 CFU/day) with or without fructooligosaccharide (FOS), versus placebo, on the absolute and relative stool abundance of L. plantarum ATCC 202195 from 14 to 60 days of age. Primary analyses will examine the effect of a 7-day regimen of L. plantarum ATCC 202195 with FOS (LP7+FOS), and secondary analyses will examine a 7-day regimen of L. plantarum ATCC 202195 without FOS (LP7), a 1-day regimen of L. plantarum ATCC 202195 with FOS (LP1+FOS), or a 1-day regimen of L. plantarum ATCC 202195 without FOS (LP1).
2. Determine if the absolute and relative stool abundance of L. plantarum ATCC 202195 from 14 to 60 days of age in Bangladeshi infants following LP1+FOS is not lower than the abundance achieved with LP7+FOS. Secondary analyses will assess the non-inferiority of the 1- and 7-day LP regimens without FOS (LP1 or LP7, respectively) compared to LP7+FOS.
3. Describe and compare the incidence and patterns of sustained and transient L. plantarum ATCC 202195 colonization (based on absolute and relative stool abundance) up to 6 months of age following administration of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, in Bangladeshi infants.
4. Assess the safety of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, during the first 60 days of age based on a) incidence of severe infection (SI) episodes associated with Lactobacillus spp.; b) incidence of detectable L. plantarum ATCC 202195 DNA in blood; c) adverse alterations in one or more biochemical or hematological parameters; and d) clinical serious adverse events.
5. Estimate the effects of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, on stool pH and concentrations of stool inflammatory markers during the first 60 days of life.
6. Assess the tolerability of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, following ingestion of the investigational product and during the period of administration (up to 21 days of age), based on frequencies and/or durations of crying time, fussiness, abdominal distention, vomiting and diarrhea.
7. Evaluate the effect of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, on stool iron content and antioxidant capacity (14 days of age) and iron status in infants (60 days of age).
8. Estimate effects of LP7+FOS, LP7, LP1+FOS and LP1, versus placebo, on infant linear growth, ponderal growth and head circumference up to 6 months of age.
9. Explore the effects of LP7+FOS, LP7, LP1+FOS or LP1, versus placebo, on the microbial community structure and diversity and metabolome of the infant's microbiota during the first 60 days of life and at 3 and 6 months of life.
10. Compare the absolute and relative stool abundance of L. plantarum ATCC 202195 in mothers and siblings of infants administered LP7+FOS, LP7, LP1+FOS, LP1, versus placebo, up to 60 days of age in the infant.
11. Assess the possible modes of cross-contamination by L. plantarum ATCC 202195 in two public hospitals, field offices, laboratories and in households within the trial catchment area in Dhaka, Bangladesh.

Study personnel will conduct active and passive clinical surveillance and routine specimen collection (e.g. stool, nasal, blood etc.). Additional specimen collection may also be triggered in the event of physician-confirmed clinical severe infection, or if infants meet the case definition of LRTI (fast breathing with at least one of the following: cough, nasal congestion, or runny nose) or are hospitalized with diarrhea and/or vomiting.

• Study Type: Interventional
• Enrollment (Actual): 519
• Phase: Phase 2

Contacts and Locations

Study Locations

• Bangladesh
  • Dhaka, Bangladesh
    • Maternal Child Health Training Institute
  • Dhaka, Bangladesh
    • Mohammadpur Fertility Services Training Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 49 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Infants up to and including four days of age*
• Infant delivered at a study hospital
• Orally feeding currently**
• Informed consent by parent or guardian
• Intends to maintain residence within the defined catchment areas (upon discharge from hospital) until 60 days of age.

Exclusion Criteria:

• Birthweight < 1500 grams***
• Death or major surgery considered to be highly probable within first week of life****
• Major congenital anomaly of the gastrointestinal tract
• Maternal HIV infection and/or history of mother ever receiving anti-retroviral drug(s) for presumed HIV infection*****
• Current mechanical ventilation and/or cardiac support (e.g., inotropes) and/or administration/prescription of parenteral antibiotics*
• Any prenatal or postpartum use of non-dietary probiotic supplement by mother during current pregnancy******
• Any postnatal administration of non-dietary probiotic or prebiotic supplements to infant
• Current participation of the infant in another clinical trial
• Resides in the same household as another infant previously enrolled in the study, or any study within the research platform, who is currently <60 days of age; however, twins may all be enrolled simultaneously in this trial.
• Multiple gestation for which the number of liveborn infants from the same pregnancy exceeds two (i.e., triplets or higher order multiples).

'*Day of birth is considered day 0 of life. Therefore, the infant could be enrolled on days 0, 1, 2, 3 or 4 of life.

'**These criteria are time-varying, so will be reassessed on a daily basis until no longer eligible for another reason (i.e., beyond day 4 of life) as long as the infant remains potentially eligible by other criteria. Orally feeding is defined as being able to take a probiotic or synbiotic supplement by mouth on a daily basis.

'***Current infant weight, as measured and documented by study personnel, will be used if birth weight is missing, illegibly recorded, or suspected of being an error (e.g., implausible value, discrepancy of greater than 15% between documented birth weight and measured screening weight).

'**** Major surgery as an operative procedure to explore and/or repair an organ or tissue that is performed under general anaesthesia. Examples relevant to the neonatal period include: ligation of patent ductus arteriosus, repair of abdominal wall defects, repair bowel perforation due to of necrotizing enterocolitis, repair of tracheoesophageal fistula and/or esophageal atresia, and repair of myelomeningocele. Conversely, examples of common procedures in newborns not considered major surgery include circumcision, tongue tie release, removal of extra digit (polydactyly).

'*****Although HIV in very young infants will be rare in this context, there is a low but non-zero theoretical risk that a baby born to an HIV positive mother could be significantly compromised, particularly in cases where in utero transmission occurred earlier in pregnancy. Both the HIV positive mother and infant are expected to represent a unique population in regards to their respective microbiomes, and excluding them should not affect generalizability of results to the population as a whole. The number of HIV positive infants is anticipated to be too low to conduct sub-group analyses and thus, it would not be possible to make meaningful inferences about this population, even if they were to be included in the study. Testing for HIV infection will not be performed as a study procedure; therefore, this criterion will be based on information available from the medical record.

'******Non-dietary probiotic supplement is a commercial (store-bought) probiotic product that is consumed in the form of a capsule, powder, liquid, etc., although it may be mixed into a food or drink at the time of consumption. In contrast, a dietary probiotic is an ingredient of a food or beverage that either occurs naturally or is added during home production or the commercial manufacturing process (e.g., yoghurt or fermented drinks).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LP7+FOS; Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg fructooligosaccharide (FOS) and 100mg maltodextrin, for 7 days.	Dietary supplement: Synbiotic; Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
Experimental: LP7; Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin, for 7 days.	Dietary supplement: Probiotic; Lactiplantibacillus plantarum ATCC 202195
Experimental: LP1+FOS; Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) with 150mg FOS and 100mg maltodextrin, for one day, followed by 6 days of placebo (250mg maltodextrin).	Other: Placebo; Maltodextrin; Dietary supplement: Synbiotic; Lactiplantibacillus plantarum ATCC 202195 with fructooligosaccharide
Experimental: LP1; Once daily oral administration of L. plantarum ATCC 202195 (10^9 CFU/day) plus 250mg maltodextrin for one day, followed by 6 days of placebo (250 mg maltodextrin).	Other: Placebo; Maltodextrin; Dietary supplement: Probiotic; Lactiplantibacillus plantarum ATCC 202195
Placebo Comparator: Placebo; Once daily oral administration of placebo (250 mg maltodextrin), for 7 days.	Other: Placebo; Maltodextrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average absolute abundance of L. plantarum ATCC 202195 in stool, measured as cells/g faces or cells/ng DNA	Absolute abundance (AA) of L. plantarum ATCC 202195 (LP202195) in stool samples refers to the log number of cells of LP202195 per mass of total extracted DNA and/or mass of stool as measured by qPCR. AA will be defined as the stool abundance of LP202195 from day 14 to 60 of age, based on up to 5 post-intervention period stool samples. However, additional analyses will involve variations on the outcome definition based on a) the age at which samples were collected and, b) timing of collection in relation to the intervention period.	Up to 60 days of age
Average relative abundance of L. plantarum ATCC 202195 in stool, measured as a ratio	Relative abundance (RA) refers to the proportion of LP202195 relative to the total bacterial load, where total bacterial load is determined by the absolute quantification of 16S rRNA gene copies as measured by qPCR. RA will be defined as the stool abundance of LP202195 from day 14 to 60 of age, based on up to 5 post-intervention period stool samples. However, additional analyses will involve variations on the outcome definition based on a) the age at which samples were collected and, b) timing of collection in relation to the intervention period.	Up to 60 days of age
Other microbial efficacy outcomes: L. plantarum ATCC 202195 Colonization	Colonization is a dichotomous variable (colonized or not) defined as a stool AA of L. plantarum ATCC 202195 that exceeds a specified threshold. Empirical distributions across all groups will be used to derive plausible thresholds of colonization based on qPCR.	Up to 60 days of age
Other microbial efficacy outcomes: Time to L. plantarum ATCC 202195 colonization	Time to colonization is defined as the earliest age (in days) at which an infant's stool had an AA value that exceeded the threshold for colonization based on qPCR.	Up to 60 days of age
Other microbial efficacy outcomes: Stool inflammatory markers	Stool inflammatory markers include stool concentrations of calprotectin (µg/g) and myeloperoxidase (ng/ml) derived from standard curves based on ELISAs.	Up to 60 days of age
Other microbial efficacy outcomes: Stool pH	Stool pH will be expressed as a continuous outcome and categorized as low if stool pH <4.5.	Up to 60 days of age

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative incidence of episodes of culture-confirmed lactobacillus spp. related severe infection (Primary clinical safety outcome)	An episode of severe infection (SI) for which the presumptive cause is Lactobacilli, implying isolation of lactobacillus spp. in blood (bacteremia), CSF (meningitis) or urine (urinary tract infection) based on conventional microbiological culture.	Up to 60 days of age
Cumulative incidence of episodes of detectable L. plantarum ATCC 202195 bacteremia (ancillary safety measure, IF FEASIBLE)	Presence of detectable L. plantarum ATCC 202915 in blood using ddPCR.	Up to 60 days of age
Frequency of hemoglobin (g/L or g/dL) below reference limit	Hemoglobin will be measured in routinely collected samples, and the proportion of values above the reference limit will be compared across intervention groups.	Up to 60 days of age
Frequency of white blood cell count (10^9 cells/L) above or below reference limit	White blood cell count will be measured in routinely collected samples, and the proportion of values above the reference limit will be compared across intervention groups.	Up to 60 days of age
Frequency of platelet count (10^9 cells/L) above or below reference limit	Platelet count will be measured in routinely collected samples, and the proportion of values above the reference limit will be compared across intervention groups.	Up to 60 days of age
Average hemoglobin (g/L or g/dL)	Hemoglobin will be measured in routinely collected samples, and the averages will be compared across intervention groups.	Up to 60 days of age
Average white blood cell count (10^9 cells/L)	White blood cell count will be measured in routinely collected samples, and the averages will be compared across intervention groups.	Up to 60 days of age
Average platelet count (10^9 cells/L)	Platelet cell count will be measured in routinely collected samples, and the averages will be compared across intervention groups.	Up to 60 days of age
Frequency of serum C-reactive protein (mg/L) above reference limit	C-reactive protein will be measured in routinely collected samples, and the proportion of values above the reference limit will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum C-reactive protein (mg/L)	C-reactive protein will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Frequency of serum procalcitonin (ug/L) above reference limit	Procalcitonin will be measured in routinely collected samples, and the proportion of values above the reference limit will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum procalcitonin (ug/L)	Procalcitonin will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum creatinine (μmol/L)	Creatinine will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum Alanine Aminotransferase (ALT) (U/L)	ALT will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum total bilirubin (μmol/L)	Bilirubin will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum conjugated bilirubin (μmol/L)	Bilirubin will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of serum albumin (g/L)	Albumin will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Average concentration of glucose (mmol/L)	Glucose will be measured in routinely collected samples, and group-average concentrations will be compared across intervention groups.	Up to 60 days of age
Safety outcomes: Serious adverse events	Serious adverse events (SAE) will be compared between groups for infants during the first 60 days of life.	Up to 60 days of age
Frequency of dripping/drooling or spitting out the dose within the first minute of IP administration; or, vomiting within 30 minutes of IP administration	Indicator of immediate post-ingestion tolerability of the investigational product	Up to 21 days of age
Frequency of maternal report of vomiting, abdominal distension, and/or diarrhea (during the period of IP administration).	Indicator of post-ingestion tolerability of the investigational product	Up to 21 days of age
Frequency of IP not administered completely on a given day after one or two attempts due to intolerance.	Indicator of incomplete or failed dose administration due to intolerance	Up to 21 days of age
Frequency of maternal report of colic-type symptoms (fuss/crying)	Indicator of post-ingestion tolerability of the investigational product	Up to 21 days of age
Anthropometric outcomes: Length for age z-scores (LAZ)	Z-scores generated based on raw lengths and INTERGROWTH-21st or World Health Organization growth standards.	Up to 6 months of age
Anthropometric outcomes: Weight for age z-scores (WAZ)	Z-scores generated based on raw weights and INTERGROWTH-21st or World Health Organization growth standards.	Up to 6 months of age
Anthropometric outcomes: Weight-for-length z-scores (WLZ)	Z-scores generated based on raw lengths and weights and INTERGROWTH-21st or World Health Organization growth standards.	Up to 6 months of age
Anthropometric outcomes: Head circumference for age z-scores (HCAZ)	Z-scores generated based on raw head circumferences and INTERGROWTH-21st or World Health Organization growth standards.	Up to 6 months of age
Incidence of severe infection	"Severe infection" (clinical outcome) defined as: at least one sign of clinical severe infection (CSI) (i.e., poor feeding, lethargy, convulsions, severe chest in-drawing, fever, or hypothermia) documented by a physician and/or physician diagnosis of sepsis or another serious bacterial infection (SBI); and at least one of the following two criteria: 1) physician decision to admit to hospital, administration of at least one dose of a parenteral antibiotic on the day when CSI/sepsis/SBI is first ascertained, and treatment with parenteral antibiotics for at least 5 days or 2) blood and/or cerebrospinal fluid culture positive for a pathogenic bacterial or fungal organism	Up to 60 days of age
Other clinical outcomes: Non-injury death	Death due to any cause except death that was directly caused by physical trauma (medically certified cause of death and/or verbal autopsy) based on mother/caregiver report	Up to 6 months of age
Other clinical outcomes: Acute diarrhea	Maternal/caregiver report of ≥3 loose stools in 24 hours for <14 days, using the modified Amsterdam scale	Up to 6 months of age
Other clinical outcomes: Persistent diarrhea	Maternal/caregiver report of frequency and consistency of stool (≥3 loose stools in 24 hours for ≥14 days) using the modified Amsterdam scale	Up to 6 months of age
Other clinical outcomes: Vomiting	Any vomiting as reported by mother/caregiver	Up to 6 months of age
Other clinical outcomes: Persistent vomiting	Vomiting ≥3 times in a 24 hour period as reported by mother/caregiver.	Up to 6 months of age
Other clinical outcomes: Hospitalization	Any inpatient admission for acute illness; excludes admission for elective surgical procedures	Up to 6 months of age
Other clinical outcomes: Cry/fuss	Cry/fuss pattern questionnaire (up to 3-months of age) based on mother/caregiver report	Up to 6 months of age
Iron status and antioxidant capacity-related biomarkers: Stool	Total iron in stool samples at day 14 of life (µg of iron/g dry weight of feces) as measured by atomic absorption spectrometry	Up to 3 months of age
Iron status-related biomarkers: Blood	Serum ferritin (µg/L). Other measures if feasible: soluble transferrin receptor (mg/L) and hepcidin (ng/ml) at day 60 of age (approx.)	Up to 3 months of age
Average absolute and relative stool abundance (as defined above) of L. plantarum ATCC 202195 detected in non-supplemented siblings and mothers of infants who received the IP.	Indicator of environmental contamination by investigational product	Up to 60 days of life (of enrolled infant)
Average number of intended doses received, irrespective of timing of dose	Indicator of adherence to investigational product	Up to 21 days of age
Average proportion of doses received by day 10 of life	Indicator of adherence to investigational product	Up to 10 days of age
Average proportion of doses received on scheduled day	Indicator of adherence to investigational product	Up to 21 days of age
Average range (in days) between first and last dose	Indicator of adherence to investigational product	Up to 21 days of age
Frequency of participant loss to follow-up	Indicator of success of participant follow-up. Loss to follow-up defined as: 1) study personnel conclusively determine that a participant cannot be further contacted for the purposes of data collection for the remaining duration of scheduled follow-up visits OR 2) three months have passed since the scheduled but missed 6-month postnatal visit.	Up to 9 months of age

Collaborators and Investigators

• Sponsor: The Hospital for Sick Children
• Collaborators: Boston University; University of California, San Diego; International Centre for Diarrhoeal Disease Research, Bangladesh; Child Health Research Foundation, Bangladesh
• Investigators: Principal Investigator: Daniel Roth, MD, PhD, The Hospital for Sick Children

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2022
• Primary Completion (Actual): June 21, 2022
• Study Completion (Actual): November 10, 2022

Study Registration Dates

• First Submitted: November 25, 2021
• First Submitted That Met QC Criteria: January 5, 2022
• First Posted (Actual): January 6, 2022

Study Record Updates

• Last Update Posted (Actual): April 13, 2023
• Last Update Submitted That Met QC Criteria: April 11, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Probiotic; Bangladesh; Synbiotic; Young infants
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Infections; Communicable Diseases
• Other Study ID Numbers: 1000072200

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: A detailed data sharing plan will be developed.
• IPD Sharing Time Frame: To be determined
• IPD Sharing Access Criteria: To be determined.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No